Ghif is a brand that is dedicated to financing innovations in global public health. Their goal is to support the development of new or improved drugs, vaccines, and medical devices for neglected diseases. With a social impact investment fund worth $108 million, Ghif focuses on late-stage innovations for public health challenges such as malaria, pre-eclampsia, cholera, HIV, and river blindness.

They prioritize infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in low- and middle-income countries. Ghif invests in projects that improve or expand access to existing products, including developing pediatric formulations of approved therapeutics and enhancing the stability of global health vaccines. They seek opportunities that have a high probability of successful commercialization within two to three years, with a particular interest in products that have both a clear impact on public health in developing countries and value in high-income countries.

They are especially interested in high-volume/low-margin products like essential vaccines. Ghif employs various investment structures, such as mezzanine debt, convertible debt, preferred equity, and project financing. They have an average investment target of approximately $10 million per project.

With each project, Ghif aims to advance their social impact objectives and show the potential to achieve commercial success